| (68)Ga-labeled peptides in tumor imaging. | |
| | |
MedLine Citation:
|
PMID: 15653666 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Radiolabeled peptides are of increasing interest in nuclear oncology. Special emphasis has been given to the development of peptides labeled with positron emitters. Among these, (68)Ga deserves special attention, because it is available from an inhouse generator rendering (68)Ga radiopharmacy independent of an onsite cyclotron. (68)Ga has a half-life of 68 min and decays by 89% through positron emission. The parent, (68)Ge, is accelerator produced and decays with a half-life of 270.8 d by electron capture. Currently, at least 1 commercial and several in-house generators are available. (68)Ge is strongly absorbed on metal oxides or organic material, making a (68)Ge-breakthrough highly unlikely. Several groups continue to further develop generators to remove cationic impurities from the eluate. Several bifunctional chelators based on 1,4,7-triazacyclononane-N,N',N''-triacetic acid and 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) macrocycles are available for coupling to peptides and other biomolecules. In addition to these hydrophilic chelators, a lipophilic tetradentate S(3)N ligand was developed. Radiopeptides for (68)Ga labeling have been developed and tested preclinically for the targeting of somatostatin receptors, the melanocortin 1 receptor, and the bombesin receptor. Clinical studies were performed with (68)Ga-DOTA,Tyr(3)-octreotide, localizing neuroendocrine tumors with higher sensitivity than (111)In-diethylenetriaminepentaacetic acid-octreotide. In addition, (68)Ga-DOTA-based bombesin derivatives are being investigated with some success in patients with prostate cancer. CONCLUSION: Generator-produced (68)Ga and the development of small chelator-coupled peptides (and other small biomolecules) may open a new generation of freeze-dried, good manufacturing practice-produced, kit-formulated PET radiopharmaceuticals similar to (99)Mo-/(99m)Tc-generator-based, (99m)Tc-labeled radiopharmaceuticals. |
| | |
Authors:
|
Helmut R Maecke; Michael Hofmann; Uwe Haberkorn |
Related Documents
:
|
7346386 - Synthesis of 2-(trimethylsilyl)ethyloxycarbonylamino acids and their use in peptide che... 3806626 - Synthetic bovine prothrombin precursor 13-29 for studies of vitamin k dependent carboxy... 2946336 - Effect of matrix modification by strong mineral acids on the positive fast atom bombard... 18937406 - Synthesis, conformational analysis and biological studies of cyclic cationic antimicrob... 432636 - Watching fat digestion. 6434516 - Isolation and characterization of an alginase from mucoid strains of pseudomonas aerugi... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 46 Suppl 1 ISSN: 0161-5505 ISO Abbreviation: J. Nucl. Med. Publication Date: 2005 Jan |
Date Detail:
|
Created Date: 2005-01-17 Completed Date: 2005-03-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 172S-8S Citation Subset: IM |
Affiliation:
|
Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Basel, Switzerland. hmaecke@uhbs.ch |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clinical Trials as Topic Drug Delivery Systems / methods* Gallium Radioisotopes / diagnostic use* Humans Neoplasms / radionuclide imaging* Peptides / diagnostic use* Physician's Practice Patterns Practice Guidelines as Topic Radiopharmaceuticals / diagnostic use |
| Chemical | |
Reg. No./Substance:
|
0/Gallium Radioisotopes; 0/Peptides; 0/Radiopharmaceuticals |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The promise of immuno-PET in radioimmunotherapy.
Next Document: Radiotargeted gene therapy.